FFA
CRNX icon

Farther Finance Advisors’s Crinetics Pharmaceuticals CRNX Stock Holding History

Farther Finance Advisors’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.41K Sell
118
-25
-17% -$929 ﹤0.01% 4864
2026
Q1 		$5.23K Sell
143
-305
-68% -$13.6K ﹤0.01% 4470
2025
Q4 		$20.9K Sell
448
-394
-47% -$17.5K ﹤0.01% 3412
2025
Q3 		$35.1K Buy
842
+707
+524% +$22.6K ﹤0.01% 2667
2025
Q2 		$3.88K Sell
135
-120
-47% -$3.71K ﹤0.01% 3454
2025
Q1 		$7.81K Sell
255
-306
-55% -$11.4K ﹤0.01% 2854
2024
Q4 		$28.7K Buy
561
+142
+34% +$7.95K ﹤0.01% 1922
2024
Q3 		$21.4K Buy
419
+412
+5,886% +$21.2K ﹤0.01% 2048
2024
Q2 		$322 Hold
7
– – ﹤0.01% 3379
2024
Q1 		$326 Hold
7
– – ﹤0.01% 3147
2023
Q4 		$249 Buy
+7
New +$215 ﹤0.01% 3177

Other funds holding CRNX

MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
LAM
Lewis Asset Management Lafayette, California $285M AUM 32.52% 1-Year Est. Return
BP
Ballentine Partners Waltham, Massachusetts $8.18B AUM 27.59% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
AA
AlphaCentric Advisors San Juan, Puerto Rico $118M AUM
PAS
Park Avenue Securities New York $16B AUM 26.77% 1-Year Est. Return

Farther Finance Advisors's CRNX Position: Q2 2026 in Review

Farther Finance Advisors reduced its Crinetics Pharmaceuticals (CRNX) stake by 17% in Q2 2026, selling an estimated $929 and leaving 118 shares worth $4.41K. The position accounts for ﹤0.01% of the portfolio, ranked #4864.

Farther Finance Advisors first reported a position in CRNX in Q4 2023 and has held it in 11 quarters since. The position peaked at $35.1K in Q3 2025. 29 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Farther Finance Advisors held 118 shares of Crinetics Pharmaceuticals worth $4.41K as of Q2 2026.
  • Farther Finance Advisors sold 25 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $929.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Farther Finance Advisors's portfolio in Q2 2026, its #4864 holding.
  • Farther Finance Advisors first reported a position in Crinetics Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
  • Farther Finance Advisors's Crinetics Pharmaceuticals position peaked at $35.1K in Q3 2025.
  • 29 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.